Skip to Main Content

Author Details

Charlie E Massie
University of Cambridge
2003
70
36
PMIDPaper TitleJournal TitlePublished Year
37431085Implementation and yield of upfront genomic profiling in a clinical prostate cancer diagnostic pathway.BJU Int2023
36170366Accurate detection of benign and malignant renal tumor subtypes with MethylBoostER: An epigenetic marker-driven learning framework.Sci Adv2022
35659150Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.Eur Urol2022
35450835Microbiomes of Urine and the Prostate Are Linked to Human Prostate Cancer Risk Groups.Eur Urol Oncol2022
36539415Dynamic partitioning of branched-chain amino acids-derived nitrogen supports renal cancer progression.Nat Commun2022
33288843Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer.Br J Cancer2021
34936871Resolving the immune landscape of human prostate at a single-cell level in health and cancer.Cell Rep2021
32450824Independence of HIF1a and androgen signaling pathways in prostate cancer.BMC Cancer2020
33015531Development of a DNA Methylation-Based Diagnostic Signature to Distinguish Benign Oncocytoma From Renal Cell Carcinoma.JCO Precis Oncol2020
32554709ctDNA monitoring using patient-specific sequencing and integration of variant reads.Sci Transl Med2020
32111235Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors.Genome Med2020
30499634Using prognosis to guide early detection and treatment selection in non-metastatic prostate cancer.BJU Int2019
30237440A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer.Oncogene2019
30389699Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models.Cancer Res2019
28870782The role of TET-mediated DNA hydroxymethylation in prostate cancer.Mol Cell Endocrinol2018
30404863Enhanced detection of circulating tumor DNA by fragment size analysis.Sci Transl Med2018
30304655Classification and Personalized Prognosis in Myeloproliferative Neoplasms.N Engl J Med2018
29662167Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.Nat Genet2018
29024710Determination of complex subclonal structures of hematological malignancies by multiplexed genotyping of blood progenitor colonies.Exp Hematol2018
27117390The importance of DNA methylation in prostate cancer development.J Steroid Biochem Mol Biol2017
28292578Corrigendum to "Integration of Copy Number and Transcriptomics Provides Risk Stratification in Prostate Cancer: A Discovery and Validation Cohort Study" [EBioMedicine 2 (9) (2015) 1133-1144].EBioMedicine2017
28501851Implementing liquid biopsies into clinical decision making for cancer immunotherapy.Oncotarget2017
28233803Liquid biopsies come of age: towards implementation of circulating tumour DNA.Nat Rev Cancer2017
28945760Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.PLoS Genet2017
28851861Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer.Nat Commun2017
28717136Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer.Sci Rep2017
28545463CVE: an R package for interactive variant prioritisation in precision oncology.BMC Med Genomics2017
27246338Methods to Identify Chromatin-Bound Protein Complexes: From Genome-Wide to Locus-Specific Approaches.Methods Mol Biol2016
26572708The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.Eur Urol2016
26635038STAT1 activation in association with JAK2 exon 12 mutations.Haematologica2016
27732966HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer.Oncotarget2016
27578825Whole blood mRNA in prostate cancer reveals a four-gene androgen regulated panel.Endocr Relat Cancer2016
27314091Kinase joins the chaperone club: Androgen-regulated kinome reveals choline kinase alpha as a potential drug target in prostate cancer.Mol Cell Oncol2016
25560400HES5 silencing is an early and recurrent change in prostate tumourigenesis.Endocr Relat Cancer2015
26250577DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype.Haematologica2015
26657335Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.J Natl Cancer Inst2015
26501111Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.EBioMedicine2015
26035357Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer.Oncotarget2015
25875424A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy.J Pathol2015
26018901Corrigendum: analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.Nat Genet2015
25671252Effect of mutation order on myeloproliferative neoplasms.N Engl J Med2015
25730763Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.Nat Genet2015
24240687N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype.Oncogene2014
25414437Nongenetic stochastic expansion of JAK2V617F-homozygous subclones in polycythemia vera?Blood2014
25288776JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response.Proc Natl Acad Sci U S A2014
25271376Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer.Elife2014
24753418The ETS family member GABPα modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer.Nucleic Acids Res2014
24837709Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer.EMBO J2014
24737870HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network.EMBO Mol Med2014
24316979Inactivating CUX1 mutations promote tumorigenesis.Nat Genet2014
  • 1 - 50 of 70

Recommended Authors

Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 10
Ren?? B??ttcher
Universitat Pompeu Fabra
Career Start Year 2012
Number of shared co-authors 4
Matti Annala
University of British Columbia
Career Start Year 2011
Number of shared co-authors 28
Julie Livingstone
University of California los angeles
Career Start Year 2011
Number of shared co-authors 16
Paul Lloyd
Bluestar Genomics Inc.
Career Start Year 2010
Number of shared co-authors 7
Housheng Hansen He
Princess Margaret Cancer Center, University Health Network, University of Toronto
Career Start Year 2010
Number of shared co-authors 15
Mohammed Alshalalfa
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 15
Alfonso Urbanucci
Northwestern University Feinberg School of Medicine Chicago
Career Start Year 2008
Number of shared co-authors 20
David A Quigley
University of California-San Francisco
Career Start Year 2008
Number of shared co-authors 8
Svitlana Tyekucheva
Dana-Farber Cancer Institute
Career Start Year 2006
Number of shared co-authors 4
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 6
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 0
Wilbert Zwart
Oncode Institute, The Netherlands Cancer Institute
Career Start Year 2004
Number of shared co-authors 9
Gong-Hong Wei
Fudan University Shanghai Cancer
Career Start Year 2004
Number of shared co-authors 14
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Career Start Year 2003
Number of shared co-authors 10
Tesa M Severson
Oncode Institute, The Netherlands Cancer Institute
Career Start Year 2002
Number of shared co-authors 11
David S Rickman
Meyer Cancer Center
Career Start Year 2001
Number of shared co-authors 3
Ilsa Coleman
Fred Hutchinson Cancer Center
Career Start Year 2001
Number of shared co-authors 9
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 0
Andrea Sboner
Institute for Computational Biomedicine
Career Start Year 2000
Number of shared co-authors 10
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 6
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 6
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 3
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 19
Holger S??ltmann
German Cancer Research Center (DKFZ)
Career Start Year 1993
Number of shared co-authors 8
Peter S Nelson
Fred Hutchinson Cancer Center
Career Start Year 1993
Number of shared co-authors 17
Guido Jenster
Erasmus University Medical Center
Career Start Year 1990
Number of shared co-authors 19
Mark A Rubin
University of Bern
Career Start Year 1990
Number of shared co-authors 30
Gyorgy Petrovics
Henry Jackson Foundation for the Advancement of Military Medicine (HJF)
Career Start Year 1990
Number of shared co-authors 14
Colin C Collins
University of British Columbia
Career Start Year 1988
Number of shared co-authors 19

Collaborators

David E Neal
University of Oxford, John Radcliffe Hospital
Co-authored papers 29
Anne Y Warren
Cambridge University Hospitals National Health Service Foundation Trust
Co-authored papers 29
Ian G Mills
Queen's University Belfast
Co-authored papers 22
Andy G Lynch
University of St Andrews
Co-authored papers 21
Hayley C Whitaker
University College London
Co-authored papers 14
Jonathan Kay
University College London
Co-authored papers 13
Vincent J Gnanapragasam
University of Cambridge
Co-authored papers 12
Colin S Cooper
Norwich Medical School, University of East Anglia
Co-authored papers 11
Alastair D Lamb
University of Oxford
Co-authored papers 11
Peter J Campbell
Wellcome Sanger Institute
Co-authored papers 10
David C Wedge
Manchester Cancer Research Centre, University of Manchester
Co-authored papers 10
Adam Butler
Wellcome Sanger Institute
Co-authored papers 9
Hayley J Luxton
University College London
Co-authored papers 8
Daniel S Brewer
University of Washington, USA Institute for Stem Cell and Regenerative Medicine
Co-authored papers 8
Rosalind A Eeles
The Institute of Cancer Research
Co-authored papers 8
Ultan McDermott
Wellcome Sanger Institute
Co-authored papers 7
Jeremy Clark
Norwich Medical School, University of East Anglia
Co-authored papers 7
Gunes Gundem
Memorial Sloan Kettering Cancer Center
Co-authored papers 7
Nimish Shah
Cambridge University Hospitals NHS Foundation Trust
Co-authored papers 7
Christopher S Foster
The Institute of Cancer Research
Co-authored papers 7
Jon Teague
Wellcome Sanger Institute
Co-authored papers 7
David Jones
Wellcome Sanger Institute
Co-authored papers 6
Helen J Ross
Mayo Clinic
Co-authored papers 6
Keiran Raine
Wellcome Sanger Institute
Co-authored papers 6
Ludmil B Alexandrov
Moores Cancer Center, university of california san diego
Co-authored papers 5
Stuart McLaren
Wellcome Trust Sanger Institute
Co-authored papers 5
Peter Van Loo
The Francis Crick Institute
Co-authored papers 5
Sandra Edwards
The Institute of Cancer Research
Co-authored papers 5
Daniel M Berney
Barts Cancer Institute, Queen Mary University of London
Co-authored papers 5
Zsofia Kote-Jarai
The Institute of Cancer Research
Co-authored papers 5
Release 1.2